Literature DB >> 22859747

Vascular disease, ESRD, and death: interpreting competing risk analyses.

Morgan E Grams1, Josef Coresh, Dorry L Segev, Lauren M Kucirka, Hocine Tighiouart, Mark J Sarnak.   

Abstract

BACKGROUND AND OBJECTIVES: Vascular disease, a common condition in CKD, is a risk factor for mortality and ESRD. Optimal patient care requires accurate estimation and ordering of these competing risks. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This is a prospective cohort study of screened (n=885) and randomized participants (n=837) in the Modification of Diet in Renal Disease study (original study enrollment, 1989-1992), evaluating the association of vascular disease with ESRD and pre-ESRD mortality using standard survival analysis and competing risk regression.
RESULTS: The method of analysis resulted in markedly different estimates. Cumulative incidence by standard analysis (censoring at the competing event) implied that, with vascular disease, the 15-year incidence was 66% and 51% for ESRD and pre-ESRD death, respectively. A more accurate representation of absolute risk was estimated with competing risk regression: 15-year incidence was 54% and 29% for ESRD and pre-ESRD death, respectively. For the association of vascular disease with pre-ESRD death, estimates of relative risk by the two methods were similar (standard survival analysis adjusted hazard ratio, 1.63; 95% confidence interval, 1.20-2.20; competing risk regression adjusted subhazard ratio, 1.57; 95% confidence interval, 1.15-2.14). In contrast, the hazard and subhazard ratios differed substantially for other associations, such as GFR and pre-ESRD mortality.
CONCLUSIONS: When competing events exist, absolute risk is better estimated using competing risk regression, but etiologic associations by this method must be carefully interpreted. The presence of vascular disease in CKD decreases the likelihood of survival to ESRD, independent of age and other risk factors.

Entities:  

Mesh:

Year:  2012        PMID: 22859747      PMCID: PMC3463208          DOI: 10.2215/CJN.03460412

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  35 in total

Review 1.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

2.  ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States.

Authors:  D Marcelli; D Stannard; F Conte; P J Held; F Locatelli; F K Port
Journal:  Kidney Int       Date:  1996-09       Impact factor: 10.612

3.  The analysis of failure times in the presence of competing risks.

Authors:  R L Prentice; J D Kalbfleisch; A V Peterson; N Flournoy; V T Farewell; N E Breslow
Journal:  Biometrics       Date:  1978-12       Impact factor: 2.571

4.  Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999.

Authors:  Robert N Foley; Anne M Murray; Shuling Li; Charles A Herzog; A Marshall McBean; Paul W Eggers; Allan J Collins
Journal:  J Am Soc Nephrol       Date:  2004-12-08       Impact factor: 10.121

5.  Withholding and withdrawing dialysis: the role of physician specialty and education and patient functional status.

Authors:  M A Sekkarie; A H Moss
Journal:  Am J Kidney Dis       Date:  1998-03       Impact factor: 8.860

6.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

Authors:  Alan S Go; Glenn M Chertow; Dongjie Fan; Charles E McCulloch; Chi-yuan Hsu
Journal:  N Engl J Med       Date:  2004-09-23       Impact factor: 91.245

Review 7.  Causes of death in autosomal dominant polycystic kidney disease.

Authors:  G M Fick; A M Johnson; W S Hammond; P A Gabow
Journal:  J Am Soc Nephrol       Date:  1995-06       Impact factor: 10.121

8.  Peripheral vascular disease: consequence for survival and association with risk factors in the Speedwell prospective heart disease study.

Authors:  D Bainton; P Sweetnam; I Baker; P Elwood
Journal:  Br Heart J       Date:  1994-08

9.  The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.

Authors:  S Klahr; A S Levey; G J Beck; A W Caggiula; L Hunsicker; J W Kusek; G Striker
Journal:  N Engl J Med       Date:  1994-03-31       Impact factor: 91.245

10.  Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization.

Authors:  Douglas S Keith; Gregory A Nichols; Christina M Gullion; Jonathan Betz Brown; David H Smith
Journal:  Arch Intern Med       Date:  2004-03-22
View more
  23 in total

1.  Association between chronic kidney disease progression and cardiovascular disease: results from the CRIC Study.

Authors:  Mahboob Rahman; Dawei Xie; Harold I Feldman; Alan S Go; Jiang He; John W Kusek; James Lash; Edgar R Miller; Akinlolu Ojo; Qiang Pan; Stephen L Seliger; Susan Steigerwalt; Ray R Townsend
Journal:  Am J Nephrol       Date:  2014-11-11       Impact factor: 3.754

2.  Past Decline Versus Current eGFR and Subsequent ESRD Risk.

Authors:  Csaba P Kovesdy; Josef Coresh; Shoshana H Ballew; Mark Woodward; Adeera Levin; David M J Naimark; Joseph Nally; Dietrich Rothenbacher; Benedicte Stengel; Kunitoshi Iseki; Kunihiro Matsushita; Andrew S Levey
Journal:  J Am Soc Nephrol       Date:  2015-12-11       Impact factor: 10.121

3.  Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and Switching.

Authors:  Anat Fisher; Greg Carney; Ken Bassett; Colin R Dormuth
Journal:  Drugs Aging       Date:  2017-03       Impact factor: 3.923

Review 4.  Assessing risk in chronic kidney disease: a methodological review.

Authors:  Morgan E Grams; Josef Coresh
Journal:  Nat Rev Nephrol       Date:  2012-11-20       Impact factor: 28.314

5.  Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies.

Authors:  Josef Coresh; Hiddo J L Heerspink; Yingying Sang; Kunihiro Matsushita; Johan Arnlov; Brad C Astor; Corri Black; Nigel J Brunskill; Juan-Jesus Carrero; Harold I Feldman; Caroline S Fox; Lesley A Inker; Areef Ishani; Sadayoshi Ito; Simerjot Jassal; Tsuneo Konta; Kevan Polkinghorne; Solfrid Romundstad; Marit D Solbu; Nikita Stempniewicz; Benedicte Stengel; Marcello Tonelli; Mitsumasa Umesawa; Sushrut S Waikar; Chi-Pang Wen; Jack F M Wetzels; Mark Woodward; Morgan E Grams; Csaba P Kovesdy; Andrew S Levey; Ron T Gansevoort
Journal:  Lancet Diabetes Endocrinol       Date:  2019-01-08       Impact factor: 32.069

Review 6.  Helping Patients With ESRD and Earlier Stages of CKD to Quit Smoking.

Authors:  Perry Formanek; Elizabeth Salisbury-Afshar; Majid Afshar
Journal:  Am J Kidney Dis       Date:  2018-04-13       Impact factor: 8.860

7.  Estimating time to ESRD using kidney failure risk equations: results from the African American Study of Kidney Disease and Hypertension (AASK).

Authors:  Morgan E Grams; Liang Li; Tom H Greene; Adrienne Tin; Yingying Sang; W H Linda Kao; Michael S Lipkowitz; Jackson T Wright; Alex R Chang; Brad C Astor; Lawrence J Appel
Journal:  Am J Kidney Dis       Date:  2014-10-14       Impact factor: 8.860

8.  Kidney Failure and ESRD in the Atherosclerosis Risk in Communities (ARIC) Study: Comparing Ascertainment of Treated and Untreated Kidney Failure in a Cohort Study.

Authors:  Casey M Rebholz; Josef Coresh; Shoshana H Ballew; Blaithin McMahon; Seamus P Whelton; Elizabeth Selvin; Morgan E Grams
Journal:  Am J Kidney Dis       Date:  2015-03-12       Impact factor: 8.860

9.  Smoking, Vascular Events, and ESRD in Patients With CKD.

Authors:  Esteban Cedillo-Couvert; Ana C Ricardo
Journal:  Am J Kidney Dis       Date:  2016-09       Impact factor: 8.860

10.  Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality.

Authors:  Josef Coresh; Tanvir Chowdhury Turin; Ron T Gansevoort; Andrew S Levey; Kunihiro Matsushita; Yingying Sang; Shoshana H Ballew; Lawrence J Appel; Hisatomi Arima; Steven J Chadban; Massimo Cirillo; Ognjenka Djurdjev; Jamie A Green; Gunnar H Heine; Lesley A Inker; Fujiko Irie; Areef Ishani; Joachim H Ix; Csaba P Kovesdy; Angharad Marks; Takayoshi Ohkubo; Varda Shalev; Anoop Shankar; Chi Pang Wen; Paul E de Jong; Kunitoshi Iseki; Benedicte Stengel
Journal:  JAMA       Date:  2014-06-25       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.